Lamivudine (3TC)-induced contact dermatitis

Cutis

Volumn 65, Issue 4, 2000, Pages 227-229

  Smith, Kathleen J ^a   Buckley, Ronald ^a   Skelton, Henry ^b,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

^c National Naval Medical Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE;

ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; PATHOLOGY; SKIN ALLERGY;

ADULT; ANTI-HIV AGENTS; DERMATITIS, ALLERGIC CONTACT; FEMALE; HUMANS; LAMIVUDINE;

EID: 0034171171     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Perry CM, Faulds D: Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 53: 657-680, 1997.
2. Katlama C, Havlir DV: Newer nucleosides: lamivudine and stavudine. AIDS 10: S135-S143, 1996.
3. Tige H, Corr M, Roman M, et al: Gene vaccination: plasmic DNA is more than just a blueprint. Immunol Today 19: 89-97, 1998.
4. Leclerc C, Ronco J: New approaches in vaccine development. Immunol Today 19: 300-302, 1998.
5. Kalish RS, Johnson KL: Enrichment and function of urushiol (poison ivy) specific T lymphocytes in lesions of allergic contact dermatitis to urushiol. J Immunol 145: 3706-3713, 1990.
6. Kalish RS: Antigen processing: the gateway to the immune response. J Am Acad Dermatol 32: 640-652, 1995.
7. Porcelli SA, Segelke BW, Sugita M, et al: The CD1 family of lipid antigen-presenting molecules. Immimol Today 19: 362-368, 1998.